Schrödinger Q2 revenue up 29% to $29.8M; net loss widens to $34.6M on investment spend

Schrodinger, Inc.

2022-Q2 EPS reported -$0.49 revenue$61,911,000

Total revenue $29.8M (+29% YoY); software revenue $24.1M (+15% YoY); drug discovery revenue $5.7M.
Net loss $34.6M vs $3.4M loss Q2 2020, driven by fair-value adjustments and R&D investments.
Announced global oncology collaboration with Zai Lab; eligible for up to ~$338M milestones and U.S. profit share.
Pipeline advancing: plans to submit up to three INDs to FDA in 2022, first IND expected H1 2022.
Full-year 2021 guidance maintained: total revenue $124M-$142M, software revenue $102M-$110M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.